Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome

World J Urol. 2006 Feb;24(1):55-60. doi: 10.1007/s00345-005-0039-x. Epub 2006 Jan 18.


To evaluate the efficacy of a terpene mixture (rowatinex) compared to ibuprofen, patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) were randomly selected to either receive rowatinex 200 mg t.i.d. or ibuprofen 600 mg t.i.d. After a 6-week treatment, the decrease in the mean total NIH-CPSI score was significant in both groups from 21.4 to 15.3, (6.1 (p < 0.01) and from 21.2 to 16.8, (4.4 (p = 0.04) in the rowatinex and ibuprofen group, respectively. The rate of definite improvement as defined as 25% improvement in the total score was superior (p = 0.04) in the rowatinex group (68%) versus the ibuprofen group (40%). Judging from these results, rowatinex gave significant symptomatic relief and may be of benefit for many men diagnosed with CP/CPPS. Further, including the placebo-controlled studies are necessary to define its role in the management of this difficult to treat disease.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Chi-Square Distribution
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Health Status Indicators
  • Humans
  • Ibuprofen / administration & dosage*
  • Male
  • Pelvic Pain / diagnosis
  • Pelvic Pain / drug therapy*
  • Probability
  • Prostatitis / diagnosis
  • Prostatitis / drug therapy*
  • Risk Assessment
  • Severity of Illness Index
  • Single-Blind Method
  • Syndrome
  • Terpenes / administration & dosage*
  • Treatment Outcome


  • Terpenes
  • Rowatinex
  • Ibuprofen